Prot #CLEE011XUS03: Modular Phase II Study to Link Targeted Therapy to Patients with Pathway Activated Tumors Module 8 – LEE011 for Patients with CDK4/6 Pathway Activated Tumors

Project: Research project

Project Details

StatusFinished
Effective start/end date12/22/1412/31/17

Funding

  • United BioSource LLC (Prot #CLEE011XUS03)
  • Novartis Pharmaceuticals Corporation (Prot #CLEE011XUS03)